Using transcriptomic data from the BELOB phase II trial, which compared lomustine versus lomustine plus bevacizumab in recurrent glioblastoma, we confirmed that CSF3 expression was overexpressed in mesenchymal tumors and correlated with VEGFA expression (see eFigure 5 in the Supplement). This evidence concerns the gene CSF3 and glioblastoma.